References
- http://wwwpathology2.jhu.edu/bladder_cancer/glossary.cfm.
- Jackson BG. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969–73.
- American Cancer Society, Inc., Surveillance Research. Cancer Faiths and Figures, 2005. http://www.geocites.com.
- World Health Organization. Cancer. February 2006. www.who.int/cancer/en. Retrieved on 25-06-2007.
- Cancer Research UK. UK cancer incidence statistics by age. January 2007. www.cancerresearchuk.org. Retrieved on 25-06-2007.
- Luc P, Stefaan VD, Mei G, Ruoli B, Ernest H, Arnold V, et al. Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization. J Med Chem 1999;42:5475–81.
- Monish J, Chul-Hoon K. 1,2-Benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. J Med Chem 2003;46:5428–36.
- Congiu C, Cocco MT, Lilliu V, Onnis V. New potential anticancer agents based on the anthranilic acid scaffold. Synthesis and evaluation of biological activity. J Med Chem 2005;48:8245–52.
- http://jjco.oupjournals.org/cgi/content/full/32/suppl_1/S13.
- Oprea TI. Virtual screening in lead discovery: a viewpoint. Molecules 2002;7:51–62.
- Leslie WD, Antony JK, Graeme JF, Bruce CB, William AD. Positioning of the carboxamide side chain in 11-oxo-11H-indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity. Bioorg Med Chem 2001;9:445–52.
- Martin YC, Kutter E, Austel V. The Medicinal Chemist’s Approach, in Modern Drug Research: Path to Better and Safer Drugs. New York: Marcel Dekker, 1989:243–307.
- Katrin MD, Stefanie L, Martin H, Manuela H, Kristian W, Michael L, et al. Synthesis of 6H-indolo[2,3-b]quinoxaline-N-glycosides and their cytotoxic activity against human ceratinocytes (HaCaT). Org Biomol Chem 2008;6:4218–23.
- Wilhelmsson LM, Ngarita K, Jan B. Interactions of antiviral indolo[2,3-b]quinoxaline derivatives with DNA. J Med Chem 2008;51:7744–50.
- Harmenberg J, Wahren B, Bergman J, Akerfeldt S, Lundblad L. Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs. Antimicrob Agents Chemother 1988;32:1720–4.
- Harmenberg J, Akesson JA, Graslund A, Malmfors T, Bergman J, Wahren B, et al. The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline. AntiViral Res 1991;15:193–204.
- Paola BA, Brigitte B, William L, Christine B, France-Aimée A, Sylvain R, et al. DNA interaction and cytotoxicity of a new series of indolo[2,3-b]quinoxaline and pyridopyrazino[2,3-b]indole derivatives. Chem Biol Interact 2001;138:59–75.
- Silva JFM, Garden SJ, Pinto AC. The chemistry of isatins: a review from 1975 to 1999. J Braz Chem Soc 2001;12:273–324.
- Yen VQ, Buu-Hoi NP, Xuong ND. Fluorinated isatins and some of their heterocyclic derivatives. J Org Chem 1958;23:1858–61.
- Skehan P, Storeng R, Scudiero D, Monks A, Mcmahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
- Palas 3.1.1.2, ADME-Tox software. Sedona, AZ: CompuDrug International Inc., 2000.
- Moorthy NSHN, Rahul S, Hemendra PS, Gupta SD. Synthesis, biological evaluation and in silico metabolic prediction of flavanone derivatives. Chem Pharm Bull 2006;54:1384–90.
- MOE molecular modeling package. Montreal: Chemical Computing Group Inc., 2002.
- Dragon web version 3.0. Milano Chemometrics and QSAR Research Group, 2003. www.disat.uinmib.it.
- ChemOffice 2001. Bethesda, MD: Adept Scientific, CambridgeSoft Corp, UK, 2001.
- Lin A. QuaSAR-descriptors. J Chem Comput Group. http://www.chemcomp.com/Journal_of_CCG/Features/descr.htm.
- SYSTAT 10.2. Chicago, IL: Systat Software Inc., 2003.
- Gupta AK. VALSTAT. Indore, India: SGSITS, 2004.
- Beresford AP, Segall M, Tarbit MH. In silico prediction of ADME properties: are we making progress? Curr Opin Drug Discov Dev 2004;7:36–42.
- Hashida M. In silico prediction of pharmacokinetic properties. Yakugaku Zasshi 2005;125:853–61.
- McGee P. New in vitro, modeling tools may cut tox attrition.Drug Discov Dev 2005;8:55–60.
- White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000;40:133–57.
- Balaji S, Karthikeyan C, Hari Narayana Moorthy NS, Trivedi P. QSAR modeling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 2004;14:6089–94.